KRBP News and Press, Kiromic BioPharma Inc. From 12/14/23

Initial Tolerability and Safety Data from First Patient Expected by Year-End, with Preliminary Efficacy Results by End of January 2024 Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) , a clinical-stage, fully-integrated biotherapeutic...

Lanvin Group Holdings Limited (LANV) is expected to report for quarter end 2023-09-30 Sonnet BioTherapeutics Holdings Inc. (SONN) is expected to report for Q4 2023 Shionogi & Co. Ltd. ADR (SGIOY) is expected to report for Q2 2024 Gelesis Holdings, Inc. (GLSHQ) is expected to repor...

JanOne Inc. (JAN) is expected to report for Q4 2023 Staffing 360 Solutions Inc. (STAF) is expected to report $-0.31 for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to report for quarter end 2023-09-30 Quotient Limited (QTNTQ) is expected to report for quarter ...

Nippon Paint Holdings Co. Ltd. (NPCPF) is expected to report for Q3 2023 SMC Corporation ADR (SMCAY) is expected to report for Q2 2024 Arcimoto Inc. (FUV) is expected to report for Q3 2023 Ever-Glory International Group Inc. (EVKG) is expected to report for quarter end 2023-09-30 ...

AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...

Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”) , a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell therapies with a focus on immu...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Company is Activating Additional Clinical Trial Sites Across the U.S. Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”) , a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND ® artificial ...

Beverly Hills Cancer Center is the first of up to four prestigious clinical sites expected to evaluate Deltacel ™ (KB-GDT-01) in patients with non-small cell lung cancer Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”) , a ...

Kiromic BioPharma Inc. (KRBP) is expected to report for quarter end 2023-06-30